Niagen Bioscience Inc (NAGE)

Currency in USD
3.660
-0.130(-3.43%)
Closed·
3.710+0.050(+1.37%)
·
NAGE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.6603.830
52 wk Range
3.56514.690
Key Statistics
Prev. Close
3.79
Open
3.82
Day's Range
3.66-3.83
52 wk Range
3.565-14.69
Volume
730.58K
Average Volume (3m)
1.21M
1-Year Change
-62.9555%
Book Value / Share
1.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NAGE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.600
Upside
+244.26%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Niagen Bioscience Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.600
(+244.26% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy11.00+200.55%12.00MaintainMay 11, 2026
Canaccord
Buy13.00+255.19%14.00MaintainMar 05, 2026
Ladenburg Thalmann
Buy12.00+227.87%11.20MaintainNov 05, 2025
Canaccord Genuity
Buy14.00+282.51%16.00MaintainNov 05, 2025
H.C. Wainwright
Buy12.00+227.87%-MaintainOct 07, 2025

Niagen Bioscience Inc Earnings Call Summary for Q3/2025

  • Niagen Bioscience (NAGE) exceeded Q3 2025 forecasts with EPS of $0.05 vs $0.02 expected and revenue of $34M vs $30.83M expected, despite stock dipping 3.73% after hours.
  • Revenue grew 33% year-over-year to $34M with net income rising to $4.6M from $1.9M in Q3 2024, driven by a 109% increase in distribution business.
  • Gross margin improved to 64.5% (up 100 basis points), with the company maintaining a strong cash position of $64.3M and no debt.
  • Management revised full-year revenue growth guidance to 25-30%, announcing plans to launch a telehealth platform for at-home injections by mid-2026.
  • Key challenges include regulatory hurdles like the FDA's NMN ruling, intense competition in NAD precursor products, and potential economic pressures on consumer spending.
Last Updated: 2025-11-04, 05:34 p/m
Read Full Transcript

Earnings

Latest Release
May 06, 2026
EPS / Forecast
0.07 / 0.08
Revenue / Forecast
31.5M / 30.23M
EPS Revisions
Last 90 days

NAGE Income Statement

Compare NAGE to Peers and Sector

Metrics to compare
NAGE
Peers
Sector
Relationship
P/E Ratio
15.7x−0.8x11.7x
PEG Ratio
0.910.000.03
Price/Book
3.5x1.6x1.5x
Price / LTM Sales
2.2x1.5x0.9x
Upside (Analyst Target)
223.9%36.1%25.3%
Fair Value Upside
Unlock23.8%13.2%Unlock

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
11.62M14.55%44.03M
Other Institutional Investors
28.28M35.44%107.19M
Public Companies & Retail Investors
39.91M50.01%151.27M
Total
79.81M100.00%302.49M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.4.85%3,871,61914,170
Nestlé S.A.4.78%3,816,79413,969

People Also Watch

4.720
NUVB
-1.46%
1.2400
ONCO
+1.64%
4.19
LFMD
+2.95%
1.89
BATL
-4.55%

FAQ

What Is the Niagen Bioscience (NAGE) Stock Price Today?

The Niagen Bioscience stock price today is 3.660 USD.

What Stock Exchange Does Niagen Bioscience Trade On?

Niagen Bioscience is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Niagen Bioscience?

The stock symbol for Niagen Bioscience is "NAGE."

What Is the Niagen Bioscience Market Cap?

As of today, Niagen Bioscience market cap is 292.110M USD.

What Is Niagen Bioscience's Earnings Per Share (TTM)?

The Niagen Bioscience EPS (TTM) is 0.210.

When Is the Next Niagen Bioscience Earnings Date?

Niagen Bioscience will release its next earnings report on Aug 12, 2026.

From a Technical Analysis Perspective, Is NAGE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Niagen Bioscience Stock Split?

Niagen Bioscience has split 1 times.

How Many Employees Does Niagen Bioscience Have?

Niagen Bioscience has 117 employees.

What is the current trading status of Niagen Bioscience (NAGE)?

As of May 23, 2026, Niagen Bioscience (NAGE) is trading at a price of 3.660 USD, with a previous close of 3.790 USD. The stock has fluctuated within a day range of 3.660 USD to 3.830 USD, while its 52-week range spans from 3.565 USD to 14.690 USD.

What Is Niagen Bioscience (NAGE) Price Target According to Analysts?

The average 12-month price target for Niagen Bioscience is 12.600 USD, with a high estimate of 18 USD and a low estimate of 10 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +244.26% Upside potential.

What Is the NAGE Premarket Price?

NAGE's last pre-market stock price is 3.819 USD. The pre-market share volume is 9,720.000, and the stock has decreased by 0.029, or 0.770%.

What Is the NAGE After Hours Price?

NAGE's last after hours stock price is 3.710 USD, the stock has decreased by 0.050, or 1.370%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.